The latest forecast from biotechnology company Mesoblast Limited shows that its core product Ryoncil is expected to generate full-year net revenue between $110 million and $120 million in fiscal year 2026.
Show original
This expectation reflects the company's confidence in the product's commercialization prospects.
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
PoolX: Earn new token airdrops
Lock your assets and earn 10%+ APR
Lock now!
You may also like
TRON Expands AI Strategy with Launch of Onchain ‘Bank of AI’ Financial Layer
CryptoNewsFlash•2026/03/02 15:05
Bitcoin ATM operator Bitcoin Depot acquires social prediction platform Kutt
Chaincatcher•2026/03/02 15:01
Trending news
MoreCrypto prices
More
Bitcoin
BTC
$67,345.91
+0.59%
Ethereum
ETH
$1,988.24
-0.83%
Tether USDt
USDT
$0.9998
-0.03%
BNB
BNB
$637.5
+1.35%
XRP
XRP
$1.37
-0.54%
USDC
USDC
$1
+0.00%
Solana
SOL
$86.34
+0.28%
TRON
TRX
$0.2821
+0.15%
Dogecoin
DOGE
$0.09398
-0.25%
Cardano
ADA
$0.2784
-0.34%
How to buy BTC
Bitget lists BTC – Buy or sell BTC quickly on Bitget!
Trade now
Become a trader now?A welcome pack worth 6200 USDT for new users!
Sign up now